Identifying optimal ALK inhibitors in first- and second-line treatment of patients with advanced ALK-positive non-small-cell lung cancer: a systematic review and network meta-analysis

To compare the efficacy, safety and effects on quality of life of different ALK-inhibitors for global and Asian patients with advanced ALK-positive non-small-cell lung cancer (NSCLC).

Source: BMC Cancer - February 8, 2024 Category: Cancer & Oncology Authors: Mingye Zhao, Taihang Shao, Hanqiao Shao, Caicun Zhou and Wenxi Tang Tags: Research Source Type: research